BIO-TECHNE CORP
TECHNASDAQTrading Snapshot
- Day Range
- $71.88 β $72.96
- 52-Week Range
- $43.20 β $72.69
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 156.6M
- Next Earnings
- Nov 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.22B
- Last Q Revenue
- $321M
- P/E Ratio
- 62.0
- P/S Ratio
- 9.3x
- EPS (TTM)
- $1.17
- Dividend Yield
- 0.44%
- Dilution (1yr)
- +0.0%
Why Investors Own TECH
- βHigh-growth profile β revenue up -3.1% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 12% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIO-TECHNE CORP
TECHAbout BIO-TECHNE CORP
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
(CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration category at the Singa

Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High β Time to Buy?
Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) hit a new 52-week high on Monday. The company traded as high as $72.70 and last traded at $72.70, with a volume of 2660 shares trading hands. The stock had previ

Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the "Company") has entered into a definitive Merger and Acquisition Agreement dated September 28, 2026, to acquire 100% of t

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to

Bio-Techne Opens New Customer Experience Center in DΓΌsseldorf to Accelerate Scientific Discovery and Customer Collaboration
New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across theΒ DACH and broader EMEA regions Center streng

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?